134 related articles for article (PubMed ID: 9612534)
1. Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease.
Karunajeewa H; Wall A; Metz J; Grigg A
Aust N Z J Med; 1998 Apr; 28(2):215-6. PubMed ID: 9612534
[No Abstract] [Full Text] [Related]
2. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.
Brewer GJ
J Cell Mol Med; 2003; 7(1):11-20. PubMed ID: 12767257
[TBL] [Abstract][Full Text] [Related]
3. Initial therapy of patients with Wilson's disease with tetrathiomolybdate.
Brewer GJ; Dick RD; Yuzbasiyan-Gurkin V; Tankanow R; Young AB; Kluin KJ
Arch Neurol; 1991 Jan; 48(1):42-7. PubMed ID: 1986725
[TBL] [Abstract][Full Text] [Related]
4. Interactions of zinc and molybdenum with copper in therapy of Wilson's disease.
Brewer GJ
Nutrition; 1995; 11(1 Suppl):114-6. PubMed ID: 7749256
[TBL] [Abstract][Full Text] [Related]
5. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
Brewer GJ
Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.
Brewer GJ; Dick RD; Johnson V; Wang Y; Yuzbasiyan-Gurkan V; Kluin K; Fink JK; Aisen A
Arch Neurol; 1994 Jun; 51(6):545-54. PubMed ID: 8198464
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease.
Xu SQ; Li XF; Zhu HY; Liu Y; Fang F; Chen L
J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):743-747. PubMed ID: 24142730
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
[TBL] [Abstract][Full Text] [Related]
9. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
10. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease.
Brewer GJ
Exp Biol Med (Maywood); 2001 Jul; 226(7):665-73. PubMed ID: 11444102
[TBL] [Abstract][Full Text] [Related]
11. Myelopathy secondary to copper deficiency as a complication of treatment of Wilson's disease.
Lozano Herrero J; Muñoz Bertrán E; Ortega González I; Gómez Espín R; López Espín MI
Gastroenterol Hepatol; 2012 Dec; 35(10):704-7. PubMed ID: 22609346
[TBL] [Abstract][Full Text] [Related]
12. Can Wilson's disease patients be decoppered?
Mason J; McQuaid A; Pheiffer H
Lancet; 1989 Jun; 1(8652):1455. PubMed ID: 2567467
[No Abstract] [Full Text] [Related]
13. Clinical considerations for an effective medical therapy in Wilson's disease.
Weiss KH; Stremmel W
Ann N Y Acad Sci; 2014 May; 1315():81-5. PubMed ID: 24754532
[TBL] [Abstract][Full Text] [Related]
14. Adverse reaction after tetrathiomolybdate treatment for Wilson's disease: a case report.
Medici V; Trevisan CP; Bigotto MA; D'Incà R; Martines D; Dal Pont E; Sturniolo GC
Mov Disord; 2006 Nov; 21(11):2030-2. PubMed ID: 16991142
[No Abstract] [Full Text] [Related]
15. Tracing copper-thiomolybdate complexes in a prospective treatment for Wilson's disease.
Zhang L; Lichtmannegger J; Summer KH; Webb S; Pickering IJ; George GN
Biochemistry; 2009 Feb; 48(5):891-7. PubMed ID: 19146437
[TBL] [Abstract][Full Text] [Related]
16. Tetrathiomolybdate causes formation of hepatic copper-molybdenum clusters in an animal model of Wilson's disease.
George GN; Pickering IJ; Harris HH; Gailer J; Klein D; Lichtmannegger J; Summer KH
J Am Chem Soc; 2003 Feb; 125(7):1704-5. PubMed ID: 12580588
[TBL] [Abstract][Full Text] [Related]
17. Thiomolybdates in the treatment of Wilson's disease.
Walshe JM
Arch Neurol; 1992 Feb; 49(2):132-3. PubMed ID: 1599534
[No Abstract] [Full Text] [Related]
18. Liver copper concentration in Wilson's disease: effect of treatment with 'anti-copper' agents.
Gibbs K; Walshe JM
J Gastroenterol Hepatol; 1990; 5(4):420-4. PubMed ID: 2129813
[TBL] [Abstract][Full Text] [Related]
19. [The onset of psychiatric disorders and Wilson's disease].
Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
[TBL] [Abstract][Full Text] [Related]
20. Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease.
Esmaeli B; Burnstine MA; Martonyi CL; Sugar A; Johnson V; Brewer GJ
Cornea; 1996 Nov; 15(6):582-8. PubMed ID: 8899270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
